MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
3.130
+0.050
+1.62%
Closed 18:15 11/25 EST
OPEN
3.090
PREV CLOSE
3.080
HIGH
3.260
LOW
3.000
VOLUME
113.06K
TURNOVER
0
52 WEEK HIGH
11.99
52 WEEK LOW
2.790
MARKET CAP
33.76M
P/E (TTM)
-1.7646
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LTRN last week (1118-1122)?
Weekly Report · 1d ago
Lantern Pharma doses first patient in LP-300 trial expansion cohort
TipRanks · 6d ago
LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN JAPAN FOR THE EXPANSION COHORT IN THE PHASE 2 HARMONIC™ CLINICAL TRIAL OF LP-300 IN NEVER-SMOKER NSCLC PATIENTS
Reuters · 6d ago
Weekly Report: what happened at LTRN last week (1111-1115)?
Weekly Report · 11/18 11:29
Weekly Report: what happened at LTRN last week (1104-1108)?
Weekly Report · 11/11 11:45
Lantern Pharma Discusses Q3 Financial Results Webinar
TipRanks · 11/08 11:28
Lantern Pharma Advances AI-Driven Cancer Therapies
TipRanks · 11/08 04:48
Lantern Pharma Q3 2024 GAAP EPS $(0.42) Beats $(0.56) Estimate
Benzinga · 11/07 21:40
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.